3Spatzenegger M,Jaeger W.Clinical importance of hepatic cytochrome P450 in drug metabolism[J].Drug Metab Rev,1995,27(3):397-417.
4Zhou S,Yung Chan S,Chef Goh B,et al.Mechanism-based inhibition of cytochrome P450 CYP3A4 by therapeutic drugs[J].Clin Pharmacokinet,2005,44(3):279-304.
5Korbonen T,Tolonen A,Unsitalo J,et al.The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel[J].Br J Clin Pharmacol,2005,60(1):69-75.
6Zebrowska L,Saymczyk G,Wrobel A.Adverse effects of interactions of antibiotics with other drugs[J].Pol Merkur Lekarski,2000,9(51):623-626.
7Zhang H,Wang B,Cui D,et al.Pharmacokinetic drug interactions involving 17-alpha-ethinylestradiol:a new look at an old drug[J].Clin Pharmacokinet,2007,46(2):133-135.
8Van Dijke CP,Weber JC.Interaction between oral contraceptives and griseofulvin[J].Br Med J(Clin Res Ed),1984,288(6424):1125-1126.
9Yasuda K,Ranade A,Venkataramanan R,et al.A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine[J].Drug Metab Dispos,2008,36(8):1689-1697.
10Ohno Y,Hisaka A,Suzuki H.General framework for the quantitative of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standerd drugs[J].Clin Pharmacokinet,2007,46(8):681-696.
二级参考文献38
1王笑中主编.新编药物学:第2版[M].北京:人民卫生出版社,1998.102.
2王振铖等译.药理作用原理[M].北京：科学出版社,1991.595.
3SchindlerAE, Mangold K, Friedrich E, Goser R. Therapy for androgenic symptomatology with cyproterone acetate and ethinylestradiol. Arch[J].Gynecol, Obstet, 1978, 225 (2): 103-107.
4Venturoli S, Paradisi R, Saviotti E, et al. Ultrasound study of ovarian and uterine morphology in women with PCOS before, during and after treatment with CPA and EE[J]. Arch Gynecol Obstet, 1985, 237(1):1 10.
5Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinylestradiol and cyproterone acetate in endocrine, clinical and ultrasonic profile in polycystie ovary syndrome[J]. Hum Reprod, 2001,16(1) : 36-42.
6Dramusic V, Goh VH, Rajan U,et al. Clinical, endocrinologic, and ultrasonographic features of polycystie ovary syndrome in Singaporean adolescents[J].J Pediatr Adolesc Gynecol, 1997,10(3) : 125-132.
7Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone, effect on premenstrual symptoms[J]. J Reprocl Med, 2002, 47(1):14 -22.
8Sangithawan M, Taneepanichskul S, Panichkul S. A comparative study of monophasie oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 btg on premenstrual symptoms[J]. Contraception, 2005, 71 (1) : 1-7.
9Oelkers WH. Drospirenone in combination with estrogens for contraception and hormone replacement therapy[J]. Climacteric, 2005, 8[Suppl 3] :19-27.
10Sillem M, Sehneidereit R, Teiehmann AT,et al. Anwendung des Drospirenon-haltigen oralen Kontrazeptivums im Langzyklus[J]. Frauenarzt, 2003, 44:876-881.
